Roger D. Tung
2021
In 2021, Roger D. Tung earned a total compensation of $3.5M as President and Chief Executive Officer at Concert Pharmaceuticals, a 17% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $367,598 |
|---|---|
| Option Awards | $1,641,743 |
| Salary | $599,426 |
| Stock Awards | $905,751 |
| Other | $12,264 |
| Total | $3,526,782 |
Tung received $1.6M in option awards, accounting for 47% of the total pay in 2021.
Tung also received $367.6K in non-equity incentive plan, $599.4K in salary, $905.8K in stock awards and $12.3K in other compensation.
Rankings
In 2021, Roger D. Tung's compensation ranked 3,790th out of 12,415 executives tracked by ExecPay. In other words, Tung earned more than 69.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,790 out of 12,415 | 70th |
Division Manufacturing | 1,549 out of 5,508 | 72nd |
Major group Chemicals And Allied Products | 629 out of 2,378 | 74th |
Industry group Drugs | 558 out of 2,099 | 73rd |
Industry Pharmaceutical Preparations | 390 out of 1,549 | 75th |
Source: SEC filing on April 26, 2022.
Tung's colleagues
We found two more compensation records of executives who worked with Roger D. Tung at Concert Pharmaceuticals in 2021.
News
Concert Pharmaceuticals CEO Roger Tung's 2021 pay rises 17% to $3.5M
April 26, 2022
Concert Pharmaceuticals CEO Roger Tung's 2020 pay rises 9% to $3M
April 27, 2021
Concert Pharmaceuticals CEO Roger Tung's 2019 pay falls 40% to $2.8M
April 28, 2020
Concert Pharmaceuticals CEO Roger Tung's 2018 pay jumps 34% to $4.6M
April 29, 2019